NCT06056752View on ClinicalTrials.gov

QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 27, 2023

Primary Completion Date

July 3, 2025

Study Completion Date

July 3, 2026

Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

QH103 Cell Injection

dose escalation (3+3) : dose 1 (3×10\^8CAR+cells) ,dose 2 (1 × 10\^9 CAR+cells）,dose 3 (3 × 10\^9CAR+cells)

DRUG

Fludarabine

Intravenous fludarabine on days-5\~-2,the infusion dose is adjusted according to the subject's condition

DRUG

Cyclophosphamide

Intravenous cyclophosphamide on days -5\~-3, the infusion dose is adjusted according to the subject's condition

Trial Locations (1)

230036

RECRUITING

Anhui Provincial Hospital, Hefei

All Listed Sponsors
lead

Anhui Provincial Hospital

OTHER_GOV